195 related articles for article (PubMed ID: 24923427)
1. Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Wong TY; Li F; Lin SM; Chan FL; Chen S; Leung LK
BMC Cancer; 2014 Jun; 14():426. PubMed ID: 24923427
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
[TBL] [Abstract][Full Text] [Related]
3. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Prosperi JR; Robertson FM
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):55-70. PubMed ID: 16997132
[TBL] [Abstract][Full Text] [Related]
5. The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.
Ye L; Chan FL; Chen S; Leung LK
J Nutr Biochem; 2012 Oct; 23(10):1230-7. PubMed ID: 22209285
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT
Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Subbaramaiah K; Howe LR; Port ER; Brogi E; Fishman J; Liu CH; Hla T; Hudis C; Dannenberg AJ
Cancer Res; 2006 May; 66(10):5504-11. PubMed ID: 16707480
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.
Li W; Jiang HR; Xu XL; Wang J; Zhang J; Liu ML; Zhai LY
Int J Mol Sci; 2010 Oct; 11(10):3999-4013. PubMed ID: 21152316
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].
Zuo CH; Li ZR; Zhou X; Ouyang YZ; Zhou ZY; Zeng L
Ai Zheng; 2006 Apr; 25(4):414-20. PubMed ID: 16613672
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
Barnes NL; Warnberg F; Farnie G; White D; Jiang W; Anderson E; Bundred NJ
Br J Cancer; 2007 Feb; 96(4):575-82. PubMed ID: 17285134
[TBL] [Abstract][Full Text] [Related]
11. Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Woditschka S; Haag JD; Mau B; Lubet RA; Gould MN
Breast Cancer Res; 2008; 10(1):R18. PubMed ID: 18279516
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.
Singh B; Irving LR; Tai K; Lucci A
J Surg Res; 2010 Oct; 163(2):235-43. PubMed ID: 20691996
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
[TBL] [Abstract][Full Text] [Related]
17. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
[TBL] [Abstract][Full Text] [Related]
18. The role of COX-2 inhibition in breast cancer treatment and prevention.
Arun B; Goss P
Semin Oncol; 2004 Apr; 31(2 Suppl 7):22-9. PubMed ID: 15179621
[TBL] [Abstract][Full Text] [Related]
19. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms.
Liu B; Wen JK; Li BH; Fang XM; Wang JJ; Zhang YP; Shi CJ; Zhang DQ; Han M
Cell Death Dis; 2011 Jul; 2(7):e185. PubMed ID: 21796157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
